As companies across the off-patent industry experience mixed fortunes in 2020 – with many firms having suffered adverse effects from the COVID-19 pandemic even in spite of short-term increases in demand enjoyed earlier in the year – Hikma has reported first-half sales and profits “ahead of our initial expectations,” with operating profit rising by 25% to $297m on sales up by 8% at $1.132bn.
Injectables sales ahead by 12% to $485m represented just over two-fifths of the total, with Generics turnover that was flat...
